Vanda Pharmaceuticals | VNDA - 流动资产



金融业
股票价格
USD
资产
USD 488.95M
现金及等价物
USD 84.85M
销售成本
USD 198.77M
流动资产
USD 347.26M
流动负债
USD 145.16M
债务
USD 4.96M
股息收益率
0
EBIT
USD -10.28M
EBITDA
USD -8.31M
员工
203
EPS每股收益
USD -0.09
股本和储备
USD 327.19M
销售毛利
USD 50.6M
债务利息支出
-1.37B
贷款资金
USD 3.15M
市值
USD 357.3M
净收入
USD -18.9M
营业费用
USD -1.14B
营业利润
USD -40.66M
普通股股本
USD 58K
PE价格收益
16.79
税前利润
USD -22.92M
销售收入
USD 198.77M
销售和管理费用
USD 39.28M
股票
USD 1.85M
贸易债权人
USD 39.09M
应收帐款人
USD 47.1M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Insmed USD 1.61B 181.04M 2026-03
J&J USD 59.17B 3.55B 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Moderna USD 5.77B 774M 2026-03
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Takeda JPY 3.09T 25.94B 2026-03
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Veracyte USD 522.17M 33.8M 2026-03